The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08, Zacks reports. Following the sale, the chief executive officer owned 591,242 shares of the company’s stock, valued at approximately $2,471,391.56. Over the last 90 days, insiders sold 26,262 shares of company stock worth $111,897. Alliance Global Partners restated a “buy” rating on shares of Verastem in a research report on Friday, May 8th. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.